TOPLINE:
According to a study of over five million patients with a neoplasm, those who received an immune checkpoint inhibitor (ICI) faced a 26% higher risk for rheumatoid arthritis (RA) than those receiving other types of cancer therapy.
METHODOLOGY:
- Researchers conducted this retrospective observational study using data from the global federated research network TriNetX to evaluate the prevalence of new-onset autoimmune conditions following the initiation of ICIs in patients with a neoplasm.
- A total of 5,259,415 patients diagnosed with a neoplasm were identified, of whom 106,809 (2.03%) received ICIs.
- Participants were divided into two groups: Those who received ICIs and those who did not. ICIs included atezolizumab, avelumab, durvalumab, dostarlimab, cemiplimab, nivolumab, pembrolizumab, ipilimumab, and tremelimumab.
- The…